“…In this context, TIA1 exerts a dual function, as it has been shown that depending on the processes regulated in different cancers, it can act both as a tumor suppressor and an oncogene [77][78][79][80]83,87,88,90,113,[172][173][174][175]. Contrastingly, TIA1 also controls processes that can prevent the development of tumors: it regulates the alternative splicing of Fas, an apoptosis receptor [37,38]; it is a translational repressor of TNFα and regulates the expression of cyclooxygenase 2 (COX2), both related to pro-inflammatory processes [41,132]; it regulates alternative splicing of the fibroblast growth-factor receptor (FGFR2) [13]; it affects the expression and can suppress signaling of HIF1α, involved in angiogenesis [65]; and it is involved in alternative splicing or post-transcriptional regulation of the tumor-suppressor genes neurofibromatosis type 1 (NF1), Wilms' tumor 1 (WT1) and programmed cell death 4 (PDCD4) [172][173][174][175]. In line with these observations and the role of TIA1 as a potential tumor suppressor, knockdown of TIA proteins in HeLa cells increases cell proliferation, tumor growth and invasion [31,89], while its overexpression leads to cell-cycle arrest, cell death and slow xenotumor development in mice [83].…”